Contact us Demo our platform

Blog

Sphingolipids’ Contribution to Inflammation and Disease States

Sphingolipids’ Contribution to Inflammation and Disease States

In conjunction with cholesterol and glycerophospholipids, sphingolipids play a key role in the membranes of eukaryotic cells.1 Cellular apoptosis, proliferation, and differentiation are modulated by sphingolipid metabolites.2 Sphingolipids include ceramide, ceramide-1-phosphate (C1P), sphingosine, sphingomyelin (SM), and sphingosine-1-phosphate (S1P).3 

Deviations in sphingolipid metabolism can cause an array of disorders.1 Thus, the study of sphingolipids correlating to infectious disease offers insights into disease states and their pathogenesis, such as pathogen receptors and impacting host defense.4-6 The relationship between sphingolipids and inflammation contributes to several disease states.3

Sphingolipids Correlate to Inflammation

Ceramide, the parent compound of sphingolipids, activates inflammation, such as neuroinflammation, when it accumulates.3,7 Further, research shows S1P’s role in driving inflammation, as S1P prompts increased p38MAPK and JNK/SPAK activation and promotes inflammatory mediators.8 Data indicates vascular inflammation may be impacted due to the proinflammatory signaling pathways induced by S1P.8 In addition, studies document C1P and S1P as contributing to intestinal inflammation post-abdominal surgery.8  

Due to their role in regard to regulating inflammation response, sphingolipids impact conditions like asthma, inflammatory bowel disease (IBD), and cystic fibrosis (CF).8

Leveraging Sphingolipids to Understand Disease States

Studies note sphingolipids’ impact on inflammation in asthma due to an ORMDL3 gene deficiency.9,10 In particular, S1P regulates cell response extra- and intracellularly through calcium mobilization.11,12 

Further, sphingolipids impact the proinflammatory response in IBD due to mutations in IL-6.13 For example, increased ceramide and SM levels correlated with chronic colitis and Crohn’s disease.3

In addition, research documents the connection between sphingolipids and cancer. In particular, derivatives from the ceramide and S1P ratios impact the regulation of cancer cell survival and death.14

Obesity, fatty liver disease, and insulin resistance are all impacted by sphingolipids, notably sphingosine and ceramide.3 Elevated levels of ceramide correlate with the reduced ability for glycogen synthesis and glucose uptake.15

Moreover, studies note variations in sphingolipid composition are connected to neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease.3 For instance, accumulation of sphingolipids occurs with aggregation of the Parkinson’s disease marker, alpha-synuclein (α-syn).3 

Sphingolipids are also implicated in lysosomal storage disorders. Studies document their role in Gaucher’s disease, Niemann–Pick disease, and gangliosidoses.3

Implications of Sphingolipids for Disease State Research

Given the growing body of research documenting the implications of sphingolipids on an array of disease states, researchers can turn to sphingolipid assays to inform their research for viable, efficacious treatments. Studies suggest the potential for substrate reduction, gene therapies, or enzyme replacement to potentially correct deviations in homeostasis.3

With Metabolon’s growing metabolite reference library and validated panels, we are excited to contribute to your sphingolipid research, helping you gain insights more quickly and ultimately get closer to understanding and combating many major diseases. Sphingolipid analysis is a fast-growing field of exploratory research, and we will continue to share our insights along with new research as discoveries are made.

Ready to see what new insights sphingolipids can help your research reveal?

Contact us today to discuss your project or study.

References

  1. Kolter T, and Sandhoff K. “Sphingolipid metabolism diseases.” Biochimica et Biophysica Acta (BBA) – Biomembranes. 2006; 1758(12): 2057-2079. https://doi.org/10.1016/j.bbamem.2006.05.027. 
  2. Hanada K. Sphingolipids in infectious diseases. Japanese journal of infectious diseases. 2005;58(3):131.
  3. Quinville BM, Deschenes NM, Ryckman AE, Walia JS. A Comprehensive Review: Sphingolipid Metabolism and Implications of Disruption in Sphingolipid Homeostasis. Int J Mol Sci. 2021;22(11):5793. doi: 10.3390/ijms22115793. 
  4. Markwell MA, Svennerholm L, Paulson JC. “Specific gangliosides function as host cell receptors for Sendai virus.” Proc. Natl. Acad. Sci. U. S. A.. 1981; 78:5406-5410. https://doi.org/10.1073/pnas.78.9.5406
  5. Karlsson KA. Animal glycosphingolipids as membrane attachment sites for bacteria. Annual review of biochemistry. 1989; 58(1):309-50.
  6. Sandvig K, van Deurs B. “Transport of protein toxins into cells: pathways used by ricin, cholera toxin Shiga toxin.” FEBS Lett. 2022; 529: 49-53.
  7. De Wit NM, Den Hoedt S, Martinez-Martinez P, Rozemuller AJ, Mulder MT, De Vries HE. Astrocytic Ceramide as Possible Indicator of Neuroinflammation. J. Neuroinflamm. 2019;16:48. doi: 10.1186/s12974-019-1436-1. 
  8. Yogi A, Callera GE, Aranha AB, Antunes TT, Graham D, Mcbride M, Dominiczak A, Touyz RM. Sphingosine-1-Phosphate-Induced Inflammation Involves Receptor Tyrosine Kinase Transactivation in Vascular Cells Upregulation in Hypertension. Hypertension. 2011. doi: 10.1161/HYPERTENSIONAHA.110.162719. 
  9. Ammit AJ, Hastie AT, Edsall LC, Hoffman RK, Amrani Y, Krymskaya VP, Kane SA, Peters SP, Penn RB, Spiegel S, et al. Sphingosine 1-Phosphate Modulates Human Airway Smooth Muscle Cell Functions That Promote Inflammation and Airway Remodeling in Asthma. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2001;15:1212–1214. doi: 10.1096/fj.00-0742fje. 
  10. Jolly PS, Rosenfeldt HM, Milstien S, Spiegel S. The Roles of Sphingosine-1-Phosphate in Asthma. Mol. Immunol. 2002;38:1239–1245. doi: 10.1016/S0161-5890(02)00070-6.
  11. Hong Choi O., Kim JH., Kinet JP. Calcium Mobilization via Sphingosine Kinase in Signalling by the FcɛRI Antigen Receptor. Nature. 1996;380:634–636. doi: 10.1038/380634a0.
  12. Prieschl EE, Csonga R, Novotny V, Kikuchi GE, Baumruker T. The Balance between Sphingosine and Sphingosine-1-Phosphate Is Decisive for Mast Cell Activation after Fc Epsilon Receptor I Triggering. J. Exp. Med. 1999;190:1–8. doi: 10.1084/jem.190.1.1.
  13. Mitselou A, Grammeniatis V, Varouktsi A, Papadatos SS, Katsanos K, Galani V. Proinflammatory Cytokines in Irritable Bowel Syndrome: A Comparison with Inflammatory Bowel Disease. Intest. Res. 2020;18:115–120. doi: 10.5217/ir.2019.00125. 
  14. Ogretmen B. Sphingolipid Metabolism in Cancer Signalling and Therapy. Nat. Rev. Cancer. 2018;18:33–50. doi: 10.1038/nrc.2017.96.
  15. Holland WL, Knotts TA, Chavez JA, Wang LP, Hoehn KL, Summers SA. Lipid Mediators of Insulin Resistance. Nutr. Rev. 2007;65:S39–S46. doi: 10.1301/nr.2007.jun.S39-S46.
Metabolon
Our team is made up of over 45 PhDs, has been published 4,000+ times, and is committed to hard work, excellence, and success through collaboration. With over 15,000 projects, Metabolon has been a trusted partner of researchers for over 25 years.

Topics

Academia / Medical Research | Inflammation

Share this article

Related Blog Posts

See All Blog Posts

GET STARTED

Talk with an expert

Request a quote, get detailed information on sample types, or learn how metabolomics can accelerate your research. Find our contact details are here.

Find us on:

Talk with a Metabolomics expert

✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.